Hancock, MD, Oct. 13, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce expansion of testing of Vitalzul™ as part of their pre-INAD studies.
In partnership with InnoVision Therapeutics, PetLife Pharmaceuticals announces the continuation of their advanced research in the pharmacological study of Vitalzul™ including toxicity, cell line and PKPD (pharmokinetics and pharmodynamics) studies in species that are symmetrical at molecular level to their target companion animal species. The studies will be conducted both via GLP and non-GLP methods as per the international standards addressing the targets.
PetLife and InnoVision expect results of their Rat Toxicity Studies within the next 30 days, allowing for progression to the Dose Range Finding Toxicology Studies for the next series of investigations. These studies are being undertaken as part of PetLife’s pre-INAD program in anticipation of a meeting with the FDA/CVM for discussion of PetLife’s Clinical and Regulatory Pathway for Vitalzul™’s registration process. These dosing parameters will also help the company advance their complimentary food and treat products using Vitalzul™ as an essential ingredient.